CClinicalTrials.gg
CompletedNCT03464994Updated Dec 31, 2025

Ophthalmological Abnormalities in Hereditary Ichthyosis (ICHTYO-KERATO)

An interventional study of ophthalmological examination in Ichthyosis, sponsored by University Hospital, Toulouse. Completed at 1 site in France. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2025-12-31.

Sponsored by University Hospital, Toulouse · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
152
Allocation
Non-randomized
Ages
6 Years and older
Sex
All
01

Study summary

Presence/absence of subclinical keratoconus with corneal topographic abnormalities (skewed radial axes for forme fruste keratoconus, and inferior steepening for keratoconus suspect) on axial specular topography (TMS-4 Tomey), and elevation topographies: Pentacam (Oculus) and Orbscan (Bausch \& Lomb).

Read the detailed description

Background: Hereditary ichthyosis are rare genetic diseases characterized by an abnormal epithelial keratinization due to mutations in gene involved in skin barrier. Patients present with scales on the whole body. Recent classification basically distinguishes syndromic from non-syndromic forms. Ichthyoses are severe diseases with significant impact on quality of life, due to troublesome symptoms (pruritus, pain), lack of effective therapy and complications such as ophthalmological anomalies. Among ophthalmological abnormalities, some are well known, such as eyelid abnormalities, including ectropion, and sicca syndrome. Conversely, corneal abnormalities such as keratoconus are not or very partially described in ichthyosis. The keratoconus is characterized by a corneal thickening and bulging with progressive loss of vision that may require a corneal transplantation. Its prevalence is 0.05% in its symptomatic presentation but may reach 10% when considering subclinical keratoconus diagnosed on basis of corneal topographies. These forme fruste keratoconus or keratoconus suspect may remain subclinical or instead progress to severe keratoconus. Corneal collagen crosslinking has been shown to strengthen the cornea in order to halt progressive keratoconus, justifying the need for early screening. Keratoconus is a complex condition of multifactorial etiology. With regards to the pathophysiology of the keratoconus, some hypotheses incriminate the corneal epithelial differentiation that is similar to the epidermal differentiation altered in ichthyosis. This link between both dermatological and ophthalmological abnormalities is supported by clinical experience. It's was observed that ichthyosis patients have frequently a subclinical keratoconus. In clinical practice, ophthalmological abnormalities are not commonly investigated in ichthyosis patients and there are no data on prevalence in the literature. Furthermore, there are no guidelines on screening or therapy of ophthalmological abnormities in ichthyosis.

The purpose of this project is to demonstrate that the prevalence of subclinical keratoconus (including forme fruste keratoconus and keratoconus suspect) is higher in ichthyosis compared to healthy controls.

Descriptive analysis of the studied population for primary outcome: The proportion of patients with subclinical keratoconus (including form fruste keratoconus and keratoconus suspect) will be described in each study-group and compared between study-groups using Mac Nemar Test.

02

Conditions studied

  • Ichthyosis

Keywords

  • Hereditary ichthyosis
  • keratoconus
03

Who can participate

Ages eligible
6 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

For ichthyosis population:

  • Hereditary ichthyosis, whatever form or ongoing therapy.
  • Parental permission for minors

For controls:

  • Patients who consult an ophthalmologist for refractive surgery screening or systematic eye examination
  • Parental permission for minors

Exclusion criteria

Exclusion Criteria:

For both populations:

  • Patient who cannot stay seated
  • Wearing contact lens within the last 7 days
  • No social security
  • Past medical history of corneal or eye surgery or eye condition (glaucoma, uveitis, keratoconus, retinal diseases)
  • Impossibility to fill the questionnaires
04

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
152 participants (actual)

Study arms

  • Other
    ichthyosis patients

    patients presenting an Hereditary ichthyosis, whatever form or ongoing therapy will have an ophthalmological examination.

    Diagnostic Test: ophthalmological examination

  • Other
    control population

    patient without ichthyosis disease and consulting an ophthalmologist for refractive surgery screening or systematic eye examination will have an ophthalmological examination

    Diagnostic Test: ophthalmological examination

Interventions

  • Diagnostic testophthalmological examination

    * Refraction * Best corrected visual acuity * Intraocular pressure * Slit lamp examination with vital dye (Oxford grading) * Tear break-up time (TBUT) * Schirmer I testing * Specular (TMS-4 Tomey) and elevation (pentacam Oculus and Orbscan Bausch \& Lomb) corneal videotopographies * Pachymetry * Questionnaires: Ocular surface disease index, quality of vision (visual analogic scale), and quality of life (NEI-VFQ25) * questionnaire about ichthyosis severity * questionnaire about life quality specifically for patient presenting ichthyosis

05

What researchers measure

Primary outcomes

  1. Presence/absence of subclinical keratoconus

    Presence/absence of subclinical keratoconus with corneal topographic abnormalities (skewed radial axes for forme fruste keratoconus, and inferior steepening for keratoconus suspect) on axial specular topography (TMS-4 Tomey), and elevation topographies: Pentacam (Oculus) and Orbscan (Bausch \& Lomb).

    Time frame: 10 mn

Secondary outcomes

  1. Presence/absence of symptomatic keratoconus with irregular topographic maps

    Evaluation by corneal videotopographies

    Time frame: 10 mn

  2. Presence/absence of an abnormality of corneal transparency

    Evaluated by the measurement of the refraction,

    Time frame: 10 mn

  3. Presence/absence of sicca syndrome

    Examination with the slit lamp of eyelids and eyelashes

    Time frame: 10 mn

  4. Evaluation of quality of vision

    -Ocular Surface Disease Index (OSDI) : Self administered form to evaluate the impact of dry eye on visual function : 12 questions rated from 0 (never) to 4 (all the time)

    Time frame: 10 mn

  5. Quality of life for adults

    -Quality of life by the National Eye Institute Visual Function Questionnaire (NEI-VFQ) : Self-administered questionnaire witch incorporates a wider range of data in relation to quality of life related to vision. Each question leads to an answer that is either dichotomous (yes / no), or graduated in 3, 4.5 and 6 points. The score of each item is transformed from 0 to 100, and the average of the scores by domain is established.

    Time frame: 10 mn

06

Study locations

1 site
  • University Hospital of Toulouse
    Toulouse, 31000, France
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03464994
Lead sponsor
University Hospital, Toulouse
Collaborators
Association for the development of research in Dermatology
Responsible party
Sponsor
First posted
Mar 14, 2018
Start date
Jul 18, 2017
Primary completion
Jun 30, 2022
Completion
Jun 30, 2022
Last update
Dec 31, 2025

Study contacts

Juliette MAZEREEUW, MD
principal investigator · University Hospital, Toulouse

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion